HLUYY - Lundbeck's Pullback Makes It Worth Considering Again
Investors often gravitate toward pharmaceutical stocks due to the perception that the sector offers less volatility than other sectors, but that has not been the case for H. Lundbeck (HLUYY) (LUN.KO), and the shares have remained quite volatile as investors try to figure out the confounding trends in both the legacy and growth portfolios, not to mention the potential future contributions of the pipeline.
While Lundbeck’s fourth quarter wasn’t bad, management was cautious with guidance. Coupled with concerns that too much of the recent earnings momentum has been driven by the legacy portfolio,